Genenta Science S.p.A.
Business
Genenta Science S.p.A. is a clinical-stage biotechnology company developing autologous ex-vivo hematopoietic stem cell gene therapies for the treatment of solid tumors. Its main product candidate, Temferon, uses a lentiviral vector to modify patient HSPCs to deliver interferon-alpha via Tie-2–expressing monocytes, and the company develops additional LVV-based payload programs and a second-generation inducible platform. Operations encompass clinical and preclinical R&D, manufacturing partnerships and licensing, and IP management. Genenta conducts clinical trials and manufacturing activities in Italy while engaging with European and U.S. regulators, opinion leaders and contract manufacturers for broader development and distribution.
Summary from filing dated 2025-03-28
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-6.50M |
| Total assets | $31.89M |
| Total liabilities | — |
| Stockholders' equity | $21.84M |
| Operating cash flow | $-6.87M |